Neurocrine Biosciences
NBIX
$166.06
+2.86%
Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company has established itself as a leader in movement disorders with its flagship product, Ingrezza, for tardive dyskinesia, and is building a diversified portfolio in rare endocrine diseases. The current investor narrative is shaped by a recent strategic acquisition to bolster its rare disease pipeline, juxtaposed against near-term stock pressure from what the market perceived as disappointing financial guidance for its key product, creating a debate between long-term growth prospects and short-term execution risks.…
NBIX
Neurocrine Biosciences
$166.06
Related headlines
Investment Opinion: Should I buy NBIX Today?
Rating & Thesis: The recommendation is a HOLD. The core thesis is that Neurocrine is a high-quality, profitable biotech with a strong balance sheet, but near-term uncertainty around Ingrezza's growth trajectory and the integration of a major acquisition justifies caution at current prices, despite a bullish analyst consensus.
Supporting Evidence: The stock trades at a forward P/E of 12.41x, which is attractive relative to its trailing multiple and implies significant earnings growth. Revenue grew 28.33% YoY in Q4, and the company generates substantial free cash flow ($748.7M TTM). However, the forward P/E's attractiveness is contingent on meeting high earnings expectations, and the stock is trading near the top of its 52-week range, leaving limited near-term upside to the average analyst target.
Risks & Conditions: The two biggest risks are Ingrezza growth deceleration and unsuccessful integration of the Soleno acquisition. This HOLD would upgrade to a BUY if the stock pulls back towards stronger technical support (e.g., below $140) or if Q3 2026 earnings demonstrate sustained Ingrezza growth and clear pipeline progress. It would downgrade to a SELL if revenue growth decelerates below 15% YoY or operating margins compress below 20%. The stock is currently fairly valued, balancing strong fundamentals with near-term execution risks.
Sign up to view all
NBIX 12-Month Price Forecast
The AI assessment is neutral based on a balance between high-quality fundamentals and near-term uncertainty. The company's profitability, cash generation, and strategic diversification efforts are compelling, but the stock's proximity to its 52-week high and the market's recent punishment for conservative guidance suggest limited near-term upside. The stance would upgrade to bullish on a pullback to the $140-$145 range, where the forward P/E offers a more compelling risk/reward, or on clear evidence of Ingrezza re-acceleration. It would turn bearish if revenue growth falls below 15% or operating margins deteriorate further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Neurocrine Biosciences's 12-month outlook, with a consensus price target around $215.88 and implied upside of +30.0% versus the current price.
Average Target
$215.88
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$133 - $216
Analyst target range
The stock is covered by 15 analysts, and the institutional sentiment is overwhelmingly bullish, as evidenced by recent reiterated 'Buy', 'Overweight', and 'Outperform' ratings from firms including JP Morgan, Wells Fargo, and RBC Capital, with only one 'Market Perform' rating noted. The consensus average revenue estimate for the next period is $5.49 billion, with a wide range from $4.84 billion to $6.26 billion, indicating significant uncertainty around the growth trajectory, particularly following the company's recent conservative guidance. The wide spread between the low and high revenue estimates signals high analyst uncertainty, likely stemming from integration risks of the Soleno acquisition and variability in the core Ingrezza franchise's performance, meaning stock price volatility could remain elevated as these narratives play out.
Bulls vs Bears: NBIX Investment Factors
The bull case is anchored in Neurocrine's robust financials—strong revenue growth, high profitability, and a fortress balance sheet—which support its strategic pivot to diversify beyond Ingrezza. The bear case centers on near-term execution risks, including heavy product concentration and margin pressure, which were highlighted by the market's negative reaction to recent guidance. Currently, the bull side holds stronger evidence due to the company's proven commercial execution, low volatility profile, and attractive forward valuation. The single most important tension in the investment debate is whether the company's strategic acquisition and pipeline investments can successfully diversify revenue before any potential slowdown in its core Ingrezza franchise materializes.
Bullish
- Strong Revenue Growth & Profitability: Q4 2025 revenue grew 28.33% YoY to $805.5M, with a robust gross margin of 97.82%. The company is solidly profitable, generating $153.7M in net income and $748.7M in TTM free cash flow, providing ample resources for pipeline investment.
- Healthy Balance Sheet & Low Volatility: The company has minimal leverage with a debt-to-equity ratio of 0.13 and a strong current ratio of 3.39. Its beta of 0.396 indicates it is approximately 60% less volatile than the market, a rarity for a biotech, suggesting it is viewed as a stable, commercial-stage entity.
- Analyst Consensus Remains Bullish: 14 of 15 analysts maintain 'Buy' or equivalent ratings, viewing the recent 10.6% stock drop on conservative guidance as a buying opportunity. This strong institutional support provides a floor for sentiment.
- Strategic Acquisition for Long-Term Growth: The acquisition of Soleno Therapeutics diversifies the pipeline into high-growth rare diseases, reducing long-term reliance on Ingrezza. This strategic move is funded by a strong cash position, avoiding dilutive financing.
Bearish
- Heavy Reliance on Single Product: Product sales, primarily from Ingrezza, constituted $798.3M of the $805.5M Q4 revenue (over 99%). This extreme concentration creates significant execution and competitive risk, as any slowdown in Ingrezza growth directly impacts the entire company.
- Recent Conservative Guidance Spooks Market: The stock dropped 10.6% on February 12th following disappointing 2026 guidance for Ingrezza, indicating near-term growth may be decelerating. This creates uncertainty, reflected in the wide analyst revenue estimate range of $4.84B to $6.26B.
- Operating Margin Compression: The Q4 operating margin of 26.18% declined from 30.07% in Q3, driven by increased R&D and SG&A investments. While necessary for growth, this trend pressures near-term profitability and must be monitored.
- Valuation Near Highs, Leaving Little Room for Error: The trailing P/E of 29.49x is near the higher end of its recent quarterly range, suggesting the market has priced in optimistic expectations. With the stock trading at 77% of its 52-week range ($158.29 vs. $169.57 high), it is susceptible to profit-taking and multiple compression.
NBIX Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 24.33% one-year price change, but is currently consolidating after a significant rally. With a current price of $158.29, it is trading at approximately 77% of its 52-week range ($122.14 to $169.57), positioning it closer to the upper bound, which suggests the momentum may be maturing and the stock could be susceptible to profit-taking near resistance. Recent momentum has been exceptionally strong, with a 23.97% gain over the past three months and a 2.55% gain over the past month, significantly outperforming the S&P 500's 15.14% and 0.74% returns over the same periods, respectively; this acceleration suggests a powerful short-term bullish impulse, potentially driven by acquisition news and earnings, though it may be overextended relative to the longer-term trend. Key technical support is at the 52-week low of $122.14, while immediate resistance is at the 52-week high of $169.57; a decisive breakout above $169.57 would signal a resumption of the primary uptrend, whereas a breakdown below $122.14 would indicate a major trend reversal. The stock exhibits low market-relative volatility with a beta of 0.396, meaning it is approximately 60% less volatile than the broader market, which is atypical for a biotech and suggests it is perceived as a more stable, commercial-stage entity.
Beta
0.40
0.40x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$122-$170
Price range past year
Annual Return
+29.6%
Cumulative gain past year
| Period | NBIX Return | S&P 500 |
|---|---|---|
| 1m | +6.0% | -1.7% |
| 3m | +25.4% | +13.7% |
| 6m | +14.3% | +6.2% |
| 1y | +29.6% | +20.8% |
| ytd | +18.1% | +7.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NBIX Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $805.5 million representing a 28.33% year-over-year increase, though this marks a deceleration from the 29.5% sequential growth seen in Q3; the vast majority of revenue ($798.3 million) is derived from product sales, primarily Ingrezza, indicating the company's heavy reliance on a single blockbuster drug for its growth trajectory. The company is solidly profitable, posting a Q4 net income of $153.7 million and an exceptionally high gross margin of 97.82%, which is consistent with its pharmaceutical business model; however, operating income of $210.9 million yields an operating margin of 26.18%, showing some compression from the 30.07% margin in Q3, likely due to increased R&D and SG&A investments. The balance sheet is very healthy, with a strong current ratio of 3.39, minimal leverage indicated by a debt-to-equity ratio of 0.128, and robust cash generation evidenced by trailing twelve-month free cash flow of $748.7 million; this substantial FCF, coupled with a return on equity of 14.71%, demonstrates the company's ability to fund its growth and pipeline expansion internally without relying on dilutive financing.
Quarterly Revenue
$805500000.0B
2025-12
Revenue YoY Growth
+0.28%
YoY Comparison
Gross Margin
+0.97%
Latest Quarter
Free Cash Flow
$748700000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NBIX Overvalued?
Given a positive net income of $153.7 million, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 29.49x and a forward PE of 12.41x; the significant gap implies the market expects a substantial near-term earnings acceleration, likely factoring in continued revenue growth and operating leverage. Compared to the biotechnology industry, a trailing PE of 29.49x is generally in line with or at a moderate premium to profitable biotech peers, which is justified by Neurocrine's commercial profitability, high margins, and diversified pipeline beyond the pre-revenue stage. Historically, the current trailing PE of 29.49x is above its own recent quarterly average seen in 2025 (which ranged from 16.65x to 348.95x, excluding the anomalous Q1 figure), placing it near the higher end of its recent band; this suggests the market is pricing in optimistic expectations for execution on its current commercial products and newly acquired pipeline assets, leaving little room for disappointment.
PE
29.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -277x~349x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Neurocrine's primary financial risk is extreme revenue concentration, with over 99% of Q4 sales coming from Ingrezza. While the company is profitable with a 16.7% net margin, operating margin compression from 30.07% in Q3 to 26.18% in Q4 signals rising costs that could pressure earnings if revenue growth decelerates further. The balance sheet is a strength, with minimal debt (D/E of 0.13) and strong cash flow, mitigating traditional financial risk but shifting focus squarely to execution risk on its core product.
Market & Competitive Risks: The stock trades at a trailing P/E of 29.49x, which is at the higher end of its recent historical band, creating valuation compression risk if growth disappoints. The recent 10.6% single-day drop on conservative guidance is a stark reminder of this sensitivity. While its low beta of 0.396 suggests it is less correlated to broad market swings than typical biotechs, the stock remains vulnerable to sector-specific sentiment shifts, particularly around drug pricing or regulatory scrutiny in neurology/psychiatry.
Worst-Case Scenario: The most damaging scenario involves a faster-than-expected slowdown in Ingrezza sales growth, coupled with pipeline setbacks for its new rare disease assets from the Soleno acquisition. This could trigger multiple analyst downgrades and a de-rating of the stock towards its 52-week low of $122.14. From the current price of $158.29, this represents a realistic downside of approximately -23%. A failure in pipeline diversification could see the stock re-price as a single-asset company with limited growth, potentially testing even lower levels.
FAQ
The key risks are, in order of severity: 1) Product Concentration Risk: Over 99% of revenue comes from Ingrezza, making the company vulnerable to any slowdown in this franchise. 2) Execution & Guidance Risk: The recent 10.6% stock drop on conservative 2026 guidance shows the market's low tolerance for perceived growth deceleration. 3) Integration Risk: The success of the Soleno acquisition is critical for long-term diversification but carries inherent execution and clinical development uncertainty. 4) Valuation Risk: Trading near its 52-week high with a trailing P/E of 29.5x, the stock is susceptible to multiple compression if growth falters.
The 12-month forecast for NBIX is a range-bound outlook with a base case target of $145-$169 (55% probability). The bull case (30% probability) targets $169-$185, requiring Ingrezza to outperform and pipeline news to be positive. The bear case (15% probability) sees a pullback to $122-$145 if growth disappoints or integration issues arise. The most likely scenario is the base case, where the company meets its guidance but lacks catalysts for a significant breakout, leading the stock to trade in line with its recent range. The key assumption is that Ingrezza growth stabilizes around 20-25% YoY.
NBIX appears fairly valued based on a mixed signal from its valuation metrics. Its trailing P/E of 29.49x is at the higher end of its recent historical range, suggesting the market is pricing in optimism. However, its forward P/E of 12.41x represents a significant discount, implying the market expects substantial earnings growth. Compared to profitable biotech peers, a ~30x trailing P/E is reasonable but not cheap. The valuation implies the market expects the company to successfully execute on its current commercial products and integrate its new acquisition to justify future growth, leaving little room for disappointment.
NBIX is a good buy for investors seeking a profitable, lower-volatility biotech with a strong balance sheet, but timing is crucial. At the current price near its 52-week high, the near-term risk/reward is balanced, as the market has priced in successful execution. The 12.41x forward P/E is attractive if the company meets its high earnings growth expectations. However, the stock's 10.6% drop on recent conservative guidance highlights its sensitivity to Ingrezza's performance. It is a better buy on a pullback, or for long-term investors willing to hold through potential volatility related to pipeline diversification.
NBIX is more suitable for a long-term investment horizon of 2-3 years or more. While its low beta of 0.396 reduces daily volatility, its sensitivity to quarterly earnings and pipeline updates makes it risky for short-term trading. The long-term thesis hinges on the successful diversification of its revenue base through the Soleno acquisition and pipeline development, which will take time to materialize. The lack of a dividend also makes it unsuitable for income-seeking investors. A minimum holding period of 12-18 months is suggested to allow the company's strategic initiatives to develop and for investors to look through near-term quarterly noise.